Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Pathology Differences Distinguish CTE from Azheimer's Disease

By LabMedica International staff writers
Posted on 01 Apr 2019
Print article
Image: These images highlight the differences found in the tau folds associated with Alzheimer\'s disease and Chronic Traumatic Encephalopathy (CTE). They also show an unidentified element found in CTE that does not exist in Alzheimer\'s disease (Photo courtesy of Indiana University School of Medicine).
Image: These images highlight the differences found in the tau folds associated with Alzheimer\'s disease and Chronic Traumatic Encephalopathy (CTE). They also show an unidentified element found in CTE that does not exist in Alzheimer\'s disease (Photo courtesy of Indiana University School of Medicine).
Neurological disease researchers have found an important difference that distinguishes the molecular pathology of Chronic Traumatic Encephalopathy (CTE) from that of Alzheimer's disease (AD).

CTE is a neurodegenerative tauopathy - a pathological aggregation of tau protein in neurofibrillary or gliofibrillary tangles in the brain - that is associated with repetitive head impacts or exposure to blast waves. It was described first as "punch-drunk syndrome" and dementia pugilistica in retired boxers, but has since been identified in former participants of other contact sports, ex-military personnel, and after physical abuse. No disease-modifying therapies currently exist, and diagnosis requires an autopsy. In AD, tau undergoes chemical changes, becoming hyperphosphorylated; it then begins to pair with other threads, creating neurofibrillary tangles and disintegrating the neuron's transport system.

Investigators at Indiana University School of Medicine (Indianapolis, USA) used cryo-electron microscopy (cryo-EM) to demonstrate a fundamental difference between the tau tangles of CTE and those of AD. Cryo-EM is an analytical technique that provides near-atomic structural resolution without requirements for crystallization or limits on molecular size and complexity imposed by the other techniques. Cryo-EM allows the observation of specimens that have not been stained or fixed in any way, showing them in their native environment while integrating multiple images to form a three-dimensional model of the sample.

The investigators determined the structures of tau filaments from the brains of three individuals with CTE at resolutions down to 2.3 Angstroms, using cryo-electron microscopy. They showed that filament structures were identical in the three cases but were distinct from those of Alzheimer’s and Pick’s diseases, and from those formed in vitro. In CTE, a different conformation of the beta-helix region created a hydrophobic cavity that was absent in tau filaments from the brains of patients with Alzheimer’s disease. This cavity enclosed an additional density that was not connected to tau, which suggested that the incorporation of cofactors may have a role in tau aggregation in CTE. The discovery of the difference between pathogenic tau of CTE and that of AD offers options for improved diagnosis and potential targeted treatments.

Contributing author Dr. Ruben Vidal, professor in the of pathology and laboratory medicine at Indiana University School of Medicine, said, "These two new discoveries provide more insights into CTE than had previously existed. The information will be incredibly valuable for the development of novel agents to help in diagnosis and therapeutics specifically designed for individuals fighting CTE."

The cryo-EM study was published in the March 20, 2019, online edition of the journal Nature.

Related Links:
Indiana University School of Medicine

New
Gold Member
Human Chorionic Gonadotropin Test
hCG Quantitative - R012
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Cytomegalovirus Test
NovaLisa Cytomegalovirus (CMV) IgG Test
New
Typhoid Rapid Test
OnSite Typhoid IgG/IgM Combo Rapid Test

Print article

Channels

Molecular Diagnostics

view channel
Image: The advanced molecular test is designed to improve diagnosis of a genetic form of COPD (Photo courtesy of National Jewish Health)

Groundbreaking Molecular Diagnostic Test Accurately Diagnoses Major Genetic Cause of COPD

Chronic obstructive pulmonary disease (COPD) and Alpha-1 Antitrypsin Deficiency (AATD) are both conditions that can cause breathing difficulties, but they differ in their origins and inheritance.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.